Emanuele Sher

Dr. Emanuele Sher


Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2004 in Current Topics in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
ESEmanuele Sher
Emanuele Sher
YCY. Chen
Y. Chen
TST.J.W. Sharples
T.J.W. Sharples
LBL.M. Broad
L.M. Broad
GBG. Benedetti
G. Benedetti
GFG. De Filippi
G. De Filippi
Nicotinic acetylcholine receptors (nAChRs) are widely expressed in the mammalian central nervous system (CNS). Despite this, very little was known, until recently, about their physiological role. In the periphery, nicotinic receptors mediate vital excitatory fast synaptic cholinergic transmission at both the neuromuscular junction and ganglia. In the brain, this role has been mainly “delegated” to glutamate receptors. The very broad cholinergic innervations of most brain areas, including the cortex, have implicated this system, and brain nicotinic receptors in particular, in a unique “modulatory” role of other transmitters systems. Recent evidence confirms, on one hand, that brain nicotinic receptors have a dominant “presynaptic” modulatory function, controlling the release of both acetylcholine (auto-receptors) and other neurotransmitters (hetero-receptors). On the other hand, more experimental data support the idea that a variable component of fast synaptic transmission in the brain can also be mediated by “postynaptic” nicotinic receptors, which, in turn, can control cell excitability. A challenging goal is to identify which one of the plethora of nicotinic receptor subtypes is mediating each effect in different brain areas, and which of these receptors and functions are lost or affected in different human neuro-psychiatric disorders. Needless to say, a better understanding of the physiological role of brain nicotinic receptors will drive our quest for more selective and efficacious nicotinic receptor targeted therapeutic agents.

1 September 2006 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Open access
PDF file
LBLisa M. Broad
Lisa M. Broad
RZRuud Zwart
Ruud Zwart
KPKathy H. Pearson
Kathy H. Pearson
MLMartin Lee
Martin Lee
LWLouise Wallace
Louise Wallace
ESEmanuele Sher
Emanuele Sher
Here we report the discovery, by high-throughput screening, of three novel (2-amino-5-keto)thiazole compounds that act as selective potentiators of nicotinic acetylcholine receptors. Compound selectivity was assessed at seven human nicotinic acetylcholine receptors (α1β1γδ, α2β4, α3β2, α3β4, α4β2, α4β4, and α7) expressed in mammalian cells or Xenopus oocytes. At α2β4, α4β2, α4β4, and α7, but not α1β1γδ, α3β2, or α3β4, submaximal responses to nicotinic agonists were potentiated in a concentration-dependent manner by all compounds. At similar concentrations, no potentiation of 5-hydroxytryptamine, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, GABAA, and N-methyl-d-aspartate receptors or voltage-gated Na+ and Ca2+ channels was observed. Furthermore, these compounds did not inhibit acetylcholine esterase. Further profiling revealed that these compounds enhanced the potency and maximal efficacy of a range of nicotinic agonists at α4β2 nicotinic acetylcholine receptors, a profile typical of allosteric potentiators. At concentrations required for potentiation, the compounds did not displace [3H]epibatidine from the agonist-binding site, and potentiation was observed at all agonist concentrations, suggesting a noncompetitive mechanism of action. Blockade of common second messenger systems did not affect potentiation. At concentrations higher then required for potentiation the compounds also displayed intrinsic agonist activity, which was blocked by competitive and noncompetitive nicotinic acetylcholine receptor (nAChR) antagonists. These novel selective nicotinic receptor potentiators should help in clarifying the potential therapeutic utility of selective nAChR modulation for the treatment of central nervous system disorders.

1 January 2014 in Molecular Pain
Verified
Journal Article
Open access
DUDaniel Ursu
Daniel Ursu
PEPhilip Ebert
Philip Ebert
ELEmily Langron
Emily Langron
CRCara Ruble
Cara Ruble
LMLeanne Munsie
Leanne Munsie
ESEmanuele Sher
Emanuele Sher
Background: Genetic causes of exaggerated or reduced pain sensitivity in humans are well known. Recently, single nucleotide polymorphisms (SNPs) in the gene P2RX7, coding for the ATP-gated ion channel P2X7, have been described that cause gain-of-function (GOF) and loss-of-function (LOF), respectively of this channel. Importantly, P2RX7 SNPs have been associated with more or less severe pain scores in patient suffering of post-mastectomy pain and osteoarthritis. Results: The functional consequences of some P2RX7 SNPs (rs208294 (His155Tyr), rs1718119 (Ala348Thr) and rs3751143 (Glu496Ala)) were studied in recombinant cells in vitro. Our findings suggest a correlation between GOF and LOF of P2X7 and actual channel protein expression. Both channel and pore function for these mutant P2X7 receptors changed in parallel to protein levels. On the other hand, the mutant receptors did not differ in their sensitivity to known P2X7 agonists and antagonists. We further demonstrated that in patients with diabetic peripheral neuropathic pain (DPNP), the presence of the GOF SNPs rs208294 (His155Tyr) and rs1718119 (Ala348Thr) is associated, in females, with higher pain intensity scores. Conclusions: Our present results confirm the physiological relevance of some of the SNPs in the P2RX7 gene and show that the presence of these genetic variants correlates with pain sensitivity also in a diabetic neuropathic pain patient population.

1 December 2003 in Journal of Bioenergetics and Biomembranes
Verified
Journal Article
Closed access
PDF file
ESEmanuele Sher
Emanuele Sher
FGF. Giovannini
F. Giovannini
ACA. Codignola
A. Codignola
MPM. Passafaro
M. Passafaro
PRPaolo Giorgi Rossi
Paolo Giorgi Rossi
PCPaola Carrera
Paola Carrera

3 March 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
MMMartina Morchio
Martina Morchio
ESEmanuele Sher
Emanuele Sher
DCDavid A. Collier
David A. Collier
DLDaniel Lambert
Daniel Lambert
FBFiona M. Boissonade
Fiona M. Boissonade
Neuropathic pain is a debilitating condition affecting around 8% of the adult population in the UK. The pathophysiology is complex and involves a wide range of processes, including alteration of neuronal excitability and synaptic transmission, dysregulated intracellular signalling and activation of pro-inflammatory immune and glial cells. In the past 15 years, multiple miRNAs–small non-coding RNA–have emerged as regulators of neuropathic pain development. They act by binding to target mRNAs and preventing the translation into proteins. Due to their short sequence (around 22 nucleotides in length), they can have hundreds of targets and regulate several pathways. Several studies on animal models have highlighted numerous miRNAs that play a role in neuropathic pain development at various stages of the nociceptive pathways, including neuronal excitability, synaptic transmission, intracellular signalling and communication with non-neuronal cells. Studies on animal models do not always translate in the clinic; fewer studies on miRNAs have been performed involving human subjects with neuropathic pain, with differing results depending on the specific aetiology underlying neuropathic pain. Further studies using human tissue and liquid samples (serum, plasma, saliva) will help highlight miRNAs that are relevant to neuropathic pain diagnosis or treatment, as biomarkers or potential drug targets.

10 September 2000 in Biochimie
Verified
Journal Article
Closed access
ESEmanuele Sher
Emanuele Sher
FGF Giovannini
F Giovannini
JBJ Boot
J Boot
BLB Lang
B Lang